DocumentsDate added
Original article
Sipra Lenka,Amit Agrawal*,Pratima Mishra
Department of Obstetrics & Gynaecology, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
Address reprint requests to:
*Amit Agrawal, Department of Obstetrics & Gynaeacology, Hi-Tech medical college and hospital, Bhubaneswar, Orissa, India
Article citation: Lenka S, Agrawal A,Mishra P. Oral misoprostol versus intravenous methylergometrine for the prevention of postpartum haemorrhage. J Pharm Biomed Sci 2016;06(06):399–400.Available at www.jpbms.info
ABSTRACT
Background Post partum haemorrhage is one of the most common causes of maternal mortality. Uterine atonicity, trauma to the genital tract, retained product of placenta are common causes of postpartum haemorrhage (PPH), out of these, atonicity contributes to a majority of cases. Many drugs have been used for the contraction of the uterus such as oxytocin, misoprostol and methylergometrine. In this study, the role of IV methylergometrine was compared with oral misoprostol for the prevention of PPH.
Materials and Methods Study of 180 women who received IV methylergometrine or oral misoprostol 600 mcg to prevent post PPH was carried out in the labour room of Hi-Tech Medical College and Hospitals, Bhubaneswar, Odisha, India, between January 2014 and January 2015.
Result In this study oral misoprostol was found to be safe, non invasive and effective method in prevention of PPH specially in low resource setting in India.
Conclusions In this study oral misoprostol was found to be safe, non invasive and effective method in prevention of PPH specially in low resource setting in India.
KEYWORDS postpartum haemorrhage, misoprostol, methylergometrine
REFERENCES
1.Ramanathan G, Arulkumaran S. Postpartum haemorrhage. Curr Obstet Gynaecol. 2006;16(1):6–13.
2.Kane TT, el-Kady AA, Saleh S, Hage M, Stanback J, Potter L. Maternal mortality in Giza, Egypt: magnitude, causes, and prevention. Stud Fam Plann. 1992;23:45–57.
3.Prendiville WJ, Elbourne D, McDonald S. Active versus expectant management in the third stage of labour. Cochrane Database Syst Rev. 2000;3:CD000007.
4.Potts M, Prata N, Walsh J, Grossman A. Parachute approach to evidence based medicine. BMJ. 2006;333:701–703.
5.Hogerzeil HV, Walker GJ. Instability of (methyl) ergometrine in tropical climates: an overview. Eur J Obstet Gynecol Reprod Biol.1996;69:25–29.
6.Hofmeyr GJ, Walraven G, Gülmezoglu AM, Maholwana B, Alfirevic Z, Villar J. Misoprostol to treat postpartum haemorrhage: a systematic review. BJOG. 2005;112:547–553.
7.Sanghvi H. Prevention of postpartum hemorrhage study, West Java, Indonesia. 2004.
8.Mousa HA, Alfirevic Z. Treatment for primary postpartum hemorrhage. Cochrane Database Syst Rev. 2007;1:CD003249 .
9.Caliskan E, Dilbaz B, Meydanli MM, Oztürk N, Narin MA, Haberal A. Oral misoprostol for the third stage of labor: a randomized controlled trial. Obstet Gynecol. 2003;101:921–928.
10.Lalonde A, Daviss BA, Acosta A, Herschderfer K. Postpartum hemorrhage today: ICM/FIGO initiative 2004-2006. Int J Gynecol Obstet. 2006;94:243–53.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.